Why the growth investor may take a look at NASDAQ:AMPH.

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

What matters for growth investors.

• In terms of Return on Equity(ROE), AMPHASTAR PHARMACEUTICALS IN is performing well, achieving a 23.0% ratio. This highlights the company's effective allocation of shareholder investments and signifies its commitment to maximizing returns.
• AMPHASTAR PHARMACEUTICALS IN has exceeded EPS estimates 3 times in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
• The 1-year revenue growth of AMPHASTAR PHARMACEUTICALS IN (30.4%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
• AMPHASTAR PHARMACEUTICALS IN has achieved 22.72% growth in its revenue over the previous quarter, signaling positive momentum in its financial performance and potential market opportunities.
• The operating margin of AMPHASTAR PHARMACEUTICALS IN has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
• The free cash flow (FCF) of AMPHASTAR PHARMACEUTICALS IN has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
• With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), AMPHASTAR PHARMACEUTICALS IN highlights its ability to generate increasing profitability, showcasing a 67.74% growth.
• AMPHASTAR PHARMACEUTICALS IN has seen a 6.44% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
• The quarterly earnings of AMPHASTAR PHARMACEUTICALS IN have shown a 67.74% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• AMPHASTAR PHARMACEUTICALS IN shows accelerating EPS growth: when comparing the current Q2Q growth of 67.74% to the previous year Q2Q growth of 31.91%, we see the growth rate improving.

What else is there to say on the fundamentals of NASDAQ:AMPH?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Taking everything into account, AMPH scores 6 out of 10 in our fundamental rating. AMPH was compared to 195 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make AMPH suitable for value investing!

For an up to date full fundamental analysis you can check the fundamental report of AMPH

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.